Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy.

Abstract

OBJECTIVES:

Our purpose was to evaluate the efficacy of antiarrhythmic drugs (AADs) in recurrent ventricular fibrillation (VF) associated with inferolateral early repolarization pattern on the electrocardiogram.

BACKGROUND:

Although an implantable cardioverter-defibrillator is the treatment of choice, additional AADs may be necessary to prevent frequent episodes of VF and reduce implantable cardioverter-defibrillator shock burden or as a lifesaving therapy in electrical storms.

METHODS:

From a multicenter cohort of 122 patients (90 male subjects, age 37 +/- 12 years) with idiopathic VF and early repolarization abnormality in the inferolateral leads, we selected all patients with more than 3 episodes of VF (multiple) including those with electrical storms (> or =3 VF in 24 h). The choice of AAD was decided by individual physicians. Follow-up data were obtained for all patients using monitoring with implantable defibrillator. Successful oral AAD was defined as elimination of all recurrences of VF with a minimal follow-up period of 12 months.

RESULTS:

Multiple episodes of VF were observed in 33 (27%) patients. Electrical storms (34 +/- 47 episodes) occurred in 16 and were unresponsive to beta-blockers (11 of 11), lidocaine/mexiletine (9 of 9), and verapamil (3 of 3), while amiodarone was partially effective (3 of 10). In contrast, isoproterenol infusion immediately suppressed electrical storms in 7 of 7 patients. Over a follow-up of 69 +/- 58 months, oral AADs were poorly effective in preventing recurrent VF: beta-blockers (2 of 16), verapamil (0 of 4), mexiletine (0 of 4), amiodarone (1 of 7), and class 1C AADs (2 of 9). Quinidine was successful in 9 of 9 patients, decreasing recurrent VF from 33 +/- 35 episodes to nil for 25 +/- 18 months. In addition, quinidine restored a normal electrocardiogram.

CONCLUSIONS:

Multiple recurrences of VF occurred in 27% of patients with early repolarization abnormality and may be life threatening. Isoproterenol in acute cases and quinidine in chronic cases are effective AADs.

• Authors: Michel Haïssaguerre, Frederic Sacher, Akihiko Nogami, Nohiriro Komiya, Anne Bernard, Vincent Probst, Sinikka Yli-Mayry, Pascal Defaye, Yoshifusa Aizawa, Robert Frank, Roberto Mantovan, Riccardo Cappato, Christian Wolpert, Antoine Leenhardt, Luc de Roy, Hein Heidbuchel, Isabel Deisenhofer, Thomas Arentz, Jean-Luc Pasquié, Rukshen Weerasooriya, Meleze Hocini, Pierre Jais, Nicolas Derval, Pierre Bordachar, Jacques Clémenty
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 53 Issue 7 Pg. 612-619 (Feb 17 2009) ISSN: 1558-3597 [Electronic] United States
• PMID: 19215837 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Quinidine
• Isoproterenol

Topics

• Adolescent
• Adult
• Anti-Arrhythmia Agents (pharmacology, therapeutic use)
• Death, Sudden, Cardiac (etiology, prevention & control)
• Defibrillators, Implantable
• Female
• Humans
• Isoproterenol (pharmacology)
• Male
• Middle Aged
• Quinidine (pharmacology)
• Recurrence
• Treatment Outcome
• Ventricular Fibrillation (complications, drug therapy, physiopathology)